FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063624406> ?p ?o ?g. }

• W2063624406 endingPage "1104" @default.
• W2063624406 startingPage "1096" @default.
• W2063624406 abstract "Second allogeneic stem cell transplants for hematological malignancies are associated with a high incidence of transplant-related mortality due to the cumulative incidence of toxicity of the high-dose chemoradiotherapy traditionally used as an essential component of the conditioning. We have demonstrated previously that nonmyeloablative conditioning for primary allogeneic transplants from both sibling and unrelated donors results in minimal transplant-related toxicity and excellent stem cell engraftment. This study explores the possibility of using nonmyeloablative conditioning to minimize transplant-related toxicity in patients who have undergone second allogeneic transplants.Twelve high-risk, heavily treated patients-five with acute myelogenous leukemia (AML); five with non-Hodgkin's lymphoma (NHL); one with Burkitt's lymphoma, and one with acute lymphoblastic leukemia (ALL)-underwent second allogeneic nonmyeloablative stem cell transplantation (NST) from human leukocyte antigen (HLA)-matched donors, 29 (median) (range 3-57) months following their first transplantation procedure. The conditioning consisted of fludarabine 30 mg/m(2) daily for 6 days, busulfan 4 mg/kg daily for 2 days, and anti-T-lymphocyte globulin 10 mg/kg daily for 4 days. Anti-graft-vs-host disease (anti-GVHD) prophylaxis consisted of cyclosporine A alone, 3 mg/kg.Engraftment was observed in all recipients, with complete and stable chimerism. None of the patients developed veno-occlusive disease of the liver or multi-organ failure. Five very high-risk patients with NHL (n = 3), Burkitt's lymphoma (n = 1), and AML (n = 1) relapsed 2 to 6 months post-transplant, and four of them died. Six patients appear to be disease-free after median follow-up of 23 months. One additional patient died from grade IV hemorrhagic cystitis. Actuarial survival and disease-free survival at 34 months are 56% and 50% respectively, with 95% confidence interval (25-78%).These results suggest that nonmyeloablative conditioning significantly reduces transplant-related toxicity, thus making a second transplant feasible." @default.
• W2063624406 created "2016-06-24" @default.
• W2063624406 creator A5030282008 @default.
• W2063624406 creator A5045116114 @default.
• W2063624406 creator A5058925624 @default.
• W2063624406 creator A5059915616 @default.
• W2063624406 creator A5072755026 @default.
• W2063624406 date "2000-09-01" @default.
• W2063624406 modified "2023-10-18" @default.
• W2063624406 title "Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation" @default.
• W2063624406 cites W1545991364 @default.
• W2063624406 cites W1707184873 @default.
• W2063624406 cites W1863755384 @default.
• W2063624406 cites W1865002508 @default.
• W2063624406 cites W1873141201 @default.
• W2063624406 cites W1933695467 @default.
• W2063624406 cites W1954992673 @default.
• W2063624406 cites W1972220493 @default.
• W2063624406 cites W1990045245 @default.
• W2063624406 cites W2022759117 @default.
• W2063624406 cites W2027671272 @default.
• W2063624406 cites W2033957812 @default.
• W2063624406 cites W2034740985 @default.
• W2063624406 cites W2035521172 @default.
• W2063624406 cites W2046478477 @default.
• W2063624406 cites W2071167148 @default.
• W2063624406 cites W2082783751 @default.
• W2063624406 cites W2085513124 @default.
• W2063624406 cites W2087184465 @default.
• W2063624406 cites W2093369626 @default.
• W2063624406 cites W2096480959 @default.
• W2063624406 cites W2121882313 @default.
• W2063624406 cites W2204379292 @default.
• W2063624406 cites W2297816245 @default.
• W2063624406 cites W2300937173 @default.
• W2063624406 cites W2334624221 @default.
• W2063624406 cites W2396781079 @default.
• W2063624406 cites W2472832889 @default.
• W2063624406 cites W3112353337 @default.
• W2063624406 cites W323623424 @default.
• W2063624406 cites W4246085869 @default.
• W2063624406 cites W4293241248 @default.
• W2063624406 cites W44995847 @default.
• W2063624406 doi "https://doi.org/10.1016/s0301-472x(00)00511-7" @default.
• W2063624406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11008023" @default.
• W2063624406 hasPublicationYear "2000" @default.
• W2063624406 type Work @default.
• W2063624406 sameAs 2063624406 @default.
• W2063624406 citedByCount "67" @default.
• W2063624406 countsByYear W20636244062012 @default.
• W2063624406 countsByYear W20636244062013 @default.
• W2063624406 countsByYear W20636244062015 @default.
• W2063624406 countsByYear W20636244062017 @default.
• W2063624406 crossrefType "journal-article" @default.
• W2063624406 hasAuthorship W2063624406A5030282008 @default.
• W2063624406 hasAuthorship W2063624406A5045116114 @default.
• W2063624406 hasAuthorship W2063624406A5058925624 @default.
• W2063624406 hasAuthorship W2063624406A5059915616 @default.
• W2063624406 hasAuthorship W2063624406A5072755026 @default.
• W2063624406 hasBestOaLocation W20636244061 @default.
• W2063624406 hasConcept C126322002 @default.
• W2063624406 hasConcept C141071460 @default.
• W2063624406 hasConcept C2776694085 @default.
• W2063624406 hasConcept C2776755627 @default.
• W2063624406 hasConcept C2777408962 @default.
• W2063624406 hasConcept C2778461978 @default.
• W2063624406 hasConcept C2778880498 @default.
• W2063624406 hasConcept C2779263901 @default.
• W2063624406 hasConcept C2779338263 @default.
• W2063624406 hasConcept C2780611847 @default.
• W2063624406 hasConcept C28328180 @default.
• W2063624406 hasConcept C2911091166 @default.
• W2063624406 hasConcept C54355233 @default.
• W2063624406 hasConcept C71924100 @default.
• W2063624406 hasConcept C86803240 @default.
• W2063624406 hasConcept C88879693 @default.
• W2063624406 hasConcept C90924648 @default.
• W2063624406 hasConceptScore W2063624406C126322002 @default.
• W2063624406 hasConceptScore W2063624406C141071460 @default.
• W2063624406 hasConceptScore W2063624406C2776694085 @default.
• W2063624406 hasConceptScore W2063624406C2776755627 @default.
• W2063624406 hasConceptScore W2063624406C2777408962 @default.
• W2063624406 hasConceptScore W2063624406C2778461978 @default.
• W2063624406 hasConceptScore W2063624406C2778880498 @default.
• W2063624406 hasConceptScore W2063624406C2779263901 @default.
• W2063624406 hasConceptScore W2063624406C2779338263 @default.
• W2063624406 hasConceptScore W2063624406C2780611847 @default.
• W2063624406 hasConceptScore W2063624406C28328180 @default.
• W2063624406 hasConceptScore W2063624406C2911091166 @default.
• W2063624406 hasConceptScore W2063624406C54355233 @default.
• W2063624406 hasConceptScore W2063624406C71924100 @default.
• W2063624406 hasConceptScore W2063624406C86803240 @default.
• W2063624406 hasConceptScore W2063624406C88879693 @default.
• W2063624406 hasConceptScore W2063624406C90924648 @default.
• W2063624406 hasIssue "9" @default.
• W2063624406 hasLocation W20636244061 @default.
• W2063624406 hasLocation W20636244062 @default.
• W2063624406 hasOpenAccess W2063624406 @default.

• next